small win: cagrilintide stopped being a problem at week 60
small win: cagrilintide stopped being a problem at week 60. Numbers below. Ask me the boring questions, they are the useful ones. Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from. Carried an assumption…
do not assume the dosing intuitions from the GLP-1 boards transfer
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
Independent result added to the log. Thank you for paying for it — there are very few on this compound.
read the combination arms separately from the monotherapy arms
phase 3 data will change most of what gets said here
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
this is a less-travelled board and the evidence base shows it
REDEFINE is the combination programme
Correcting myself upthread: I gave the 23-week figure and the paper reports 72 weeks.
nothing containing this is approved as a standalone product